Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and if seizures are well controlledXx_NEWLINE_xXPatients who are currently receiving enzyme inducing anticonvulsants are not eligibleXx_NEWLINE_xXPatients must not have received enzyme-inducing anticonvulsants including phenytoin, phenobarbital, valproic acid, or carbamazepine for at least 7 days prior to study enrollment; patients receiving non-enzyme inducing anticonvulsants such as gabapentin or levetiracetam will be eligibleXx_NEWLINE_xXTUMOR BIOPSY SEQUENCING: Patients with history of central nervous system (CNS) metastases who have received treatment and who either have not had seizures or have been on stable doses of anti-seizure medicine and had no seizures for 4 weeks will be eligible; enzyme-inducing anticonvulsants are contraindicatedXx_NEWLINE_xXTREATMENT: Patients with a history of seizures are not eligible to receive veliparib, but patients with a history of CNS metastases who have received treatment and who either have not had seizures or have been on stable doses of anti-seizure medicine and had no seizures for >= 4 weeks will be eligible for other study agents; enzyme inducing anticonvulsants are contraindicatedXx_NEWLINE_xXTREATMENT: Patients with active brain metastases or carcinomatous meningitis are excluded from this clinical trial; patients who have a history of seizures are not eligible to receive veliparib, but patients who have either not had seizures or who have been on stable doses of anti-seizure medicine and had no seizures for 4 weeks will be eligible for other study agents; enzyme-inducing anticonvulsants are contraindicatedXx_NEWLINE_xXPatients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlledXx_NEWLINE_xXPatients must not currently be receiving enzyme inducing anticonvulsantsXx_NEWLINE_xXPatients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlledXx_NEWLINE_xXPatients must not have received enzyme inducing anticonvulsants for at least 14 days prior to enrollmentXx_NEWLINE_xXPatients with seizure disorder may be enrolled if on anticonvulsants and well controlledXx_NEWLINE_xXPatients with seizure disorder may be enrolled if on anticonvulsants and if seizures are well controlledXx_NEWLINE_xXCentral nervous system function defined as:* Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled* Patients must not be in status epilepticus, a coma or on assisted ventilation at the time of study enrollmentXx_NEWLINE_xXPatients with seizure disorder may be enrolled if on anticonvulsants and well controlledXx_NEWLINE_xXPatients with a known seizure disorder who are receiving non-enzyme inducing anticonvulsants and have well-controlled seizures may be enrolledXx_NEWLINE_xXPatients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlledXx_NEWLINE_xXPatients must not have received enzyme-inducing anticonvulsants for at least 7 days prior to enrollmentXx_NEWLINE_xXPatients with seizure disorder may be enrolled if on anticonvulsants and well controlledXx_NEWLINE_xXPatients with seizure disorder may be enrolled if on anticonvulsants and well controlledXx_NEWLINE_xX